Xenograft News and Research

RSS

Xenograft are the cells of one species transplanted to another species.

Improving cancer therapies by exploiting drug resistance in cancer

News-Medical talks to Professor David Thomas about his recent research identifying the mechanisms behind cancer cells developing resistance to drugs.

23 Jun 2020

TissueGnostics achieves milestone in research community

TissueGnostics is pleased to announce achieving a new level of confidence within the international biomedical research community. As of May 2020, TissueGnostics has been referenced in over 1,500 individual research publications. High impact research made possible by TissueGnostics, emerging from 59 countries on 6 continents, results in a sum impact factor of 8,700.

From TissueGnostics 26 May 2020

Kurome secures license to develop novel therapies for chemo-resistant cancer

Seed investor CincyTech announced the formation of Kurome Therapeutics ("Kurome"), a preclinical stage company developing novel therapies targeting cancer cells' adaptive resistance mechanisms beginning with hematopoietic, or blood cell, cancers.

29 Apr 2020

Advancing CAR T-cell therapy for treatment of solid tumors

The full title of the research is "The study of the mechanisms of effectiveness of T-cells CAR-T towards solid tumors"; it was supported by nonprofit RakFond (Cancer Fund) and CyStoreLab (a resident of Skolkovo).

25 Mar 2020

Targeting PI3Kβ alone and with combination therapy in PTEN-deficient tumors

The cover for issue 11 of Oncotarget features Figure 6, "Effects of AZD8186 in combination with anti-PD1 on syngeneic models," by Owusu-Brackett, et al.

18 Mar 2020

New discovery could lead to better strategies for preventing breast cancer metastasis

New discovery in breast cancer could lead to better strategies for preventing the spread of cancer cells to other organs in the body, effectively reducing mortality in breast cancer patients.

8 Mar 2020

Study provides new insight into neurofibromin-deficient ER+ breast cancer

An international team of researchers led by scientists at Baylor College of Medicine has new insights into the function of neurofibromin, a tumor suppressor produced by the NF1 gene.

5 Mar 2020

P53-deficient oral cancers recruit and reprogram nerves to fuel tumor growth

Loss of an important tumor-suppressing gene allows head and neck cancer to spin off signals to nearby nerves, changing their function and recruiting them to the tumor, where they fuel growth and cancer progression, researchers from The University of Texas MD Anderson Cancer Center report in the journal Nature today.

13 Feb 2020

Researchers develop first non-invasive way to monitor oxygen in tumors during radiation therapy

Oxygen in cancer tumors is known to be a major factor that helps radiation therapy be successful. Hypoxia, or starvation of oxygen, in solid tumors is also thought to be an important factor in resistance to therapy.

29 Jan 2020

Study may provide novel targetable mechanisms of therapeutic resistance to anti-VEGF therapies

To establish a molecular signature of this resistance in ovarian cancer, the authors developed preclinical tumor models of adaptive resistance to chronic anti-VEGF treatment.

8 Jan 2020

Daily aspirin use may help prevent colorectal cancer

A new study has shown that regular use of aspirin may protect against heart disease, reduce colorectal tumor growth and prevent relapse.

7 Jan 2020

Mount Sinai awarded more than $10 million in federal funding for research on glioblastoma

The Department of Neurosurgery at the Icahn School of Medicine at Mount Sinai has received more than $10 million in federal funding for several projects focusing on brain tumor research.

2 Jan 2020

Catastrophic macropinocytosis may aid in cancer treatment

In laboratory experiments, a metabolic inhibitor was able to kill a variety of human cancer cells of the skin, breast, lung, cervix and soft tissues through a non-apoptotic route -- catastrophic macropinocytosis.

18 Dec 2019

Novel and targeted cellular product causes cell death in non-Hodgkin lymphoma models

Investigators at Rutgers Cancer Institute of New Jersey have found that a treatment based on a novel cellular product programmed to deliver an overabundance of chimeric antigen receptor causes cell death in non-Hodgkin lymphoma models that are sensitive or resistant to standard therapies.

16 Dec 2019

Study: Calcium signaling can help address drug resistance to non-Hodgkin lymphoma

Gene expression profiling and other analyses conducted by Rutgers Cancer Institute of New Jersey researchers and colleagues examining drug resistance to a common antibody therapy for non-Hodgkin lymphoma have identified calcium signaling as a novel and exploitable target in overcoming this treatment obstacle.

3 Dec 2019

Xenograft News and Research

Improving cancer therapies by exploiting drug resistance in cancer

TissueGnostics achieves milestone in research community

Kurome secures license to develop novel therapies for chemo-resistant cancer

Advancing CAR T-cell therapy for treatment of solid tumors

Targeting PI3Kβ alone and with combination therapy in PTEN-deficient tumors

New discovery could lead to better strategies for preventing breast cancer metastasis

Study provides new insight into neurofibromin-deficient ER+ breast cancer

P53-deficient oral cancers recruit and reprogram nerves to fuel tumor growth

Researchers develop first non-invasive way to monitor oxygen in tumors during radiation therapy

Study may provide novel targetable mechanisms of therapeutic resistance to anti-VEGF therapies

Daily aspirin use may help prevent colorectal cancer

Mount Sinai awarded more than $10 million in federal funding for research on glioblastoma

Catastrophic macropinocytosis may aid in cancer treatment

Novel and targeted cellular product causes cell death in non-Hodgkin lymphoma models

Study: Calcium signaling can help address drug resistance to non-Hodgkin lymphoma

Apoptosis protein API-5 more markedly expressed in chemoresistant triple-negative breast cancer

Clinical analysis reveals high expression of apoptosis protein in chemoresistant TNBC

New method may offer effective treatment for pancreatic cancer with fewer side effects

Yale scientists build powerful genomic research platform to study cervical cancer

Live-cell, genetically engineered pig skin used for temporary closure of a burn wound

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News